Efficacy of some living classical and variant infectious bronchitis vaccines against local variant isolated from Egypt.

Susan, S. El- Mahdy; Ekram, Salama and Amal, Ahmed
Prof.s.elmahdy@gmail.com.

Abstract: This study was designed to evaluate the protection induced by different living classical and variant infectious bronchitis vaccines (IB vaccines) against local variant isolated from Egypt at 2012. Two hundred and forty one day old Specific-pathogen-free (SPF) chicks were divided into eight groups. Groups (1-3) were vaccinated with three different variant infectious bronchitis living vaccine and group (4-6) with three different classical one. Groups (7&8) did not receive IBV vaccine and served as (+ve and –ve) controls respectively. Three weeks post vaccination, the chickens in groups (1-7) were individually challenged with 10^{4.0} EID_{50} of IB (IS/885). The protection was evaluated at 7 days post-inoculation. The results of this study showed that we can use IB-88; IB primers (variant) and Ma5 (classical) vaccines as a method for controlling IB infection in Egypt. [Susan, S. El- Mahdy; Ekram, Salama and Amal, Ahmed. Efficacy of some living classical and variant infectious bronchitis vaccines against local variant isolated from Egypt. Nat Sci 2012;10(12):292-299]. (ISSN: 1545-0740).
http://www.sciencepub.net/nature. 44

Key words: Infectious bronchitis vaccines; chickens; local variant strain.

1. Introduction
The Egyptian poultry industry in recent years has observed an increasing incidence of respiratory and nephritis pathologies related to infection with infectious bronchitis virus (IBV) in vaccinated and non-vaccinated flocks that caused severe economic losses. (Susan et al., 2010). IBV was firstly described as a highly contagious pathogen in chickens in the late 1930s (Schalk and Hawn, 1931). During 1950s IB infection was firstly recognized in Egyptian farms by Ahmed (1954) and confirmed by Eissa et al., (1963) from birds showing respiratory signs.

IBV is a member of the Corona-virus and which considered a major cause of respiratory infection in broiler and poor egg laying in breeders and layers, which replicated primarily in respiratory tract and also in some epithelial cells of the gut, kidney and oviduct (Cavanagh and Nagi 2003; Wu et al., 2010) some stains of IBV can cause acute nephritis and urolithiasis associated with a high mortality rate in infected chickens (Ziegler et al., 2003; Schalk and Hawn, 1931). IBV complete protection is provided by vaccination with homologous strains however, partial protection may be provided after vaccination with a live attenuated heterologous strain (Wang et al., 1996; Liu et al., 2009). Although many strains of vaccine are commercially available at present, it is unknown whether the currently used vaccines offer enough cross-protective capability against the IBV strains present in the field in Egypt.

Consequently these emergences are of great concern to poultry producers. Since the isolation of IBV from chickens suffering from respiratory or renal problem in Egypt (Ahmed 1964). IB has continued to be an economically important disease in the Egypt poultry industry and has been found all over the country. Many researchers isolated IBV related to Massachusetts, D3128, D274, D-0880, 4/91, Egypt / Beni-Suef /01; Egypt/F/03 and IS/1494/06 were isolated from different poultry farms (Amin and Moustagger 1977.; Sheble et al., 1986; Bastami et al., 1987; El-Kady 1989; Eid Amal. 1994; El-Sisi and Eid Amal. 2000; Abdel Moneim et al., 2002 and 2006; Sultan et al., 2004 and Susan et al., 2010). IB complete protection is provided by vaccination with homologous strains however, partial protection may be provided after vaccination with a live attenuated heterologous strain (Wang et al., 1996; Liu et al., 2009). Although many strains of vaccine are commercially available at present, it is unknown whether the currently used vaccines offer enough cross-protective capability against the IBV strains present in the field in Egypt.

Hence, the objective of the present study was to examine the protection afforded by some living classical and variant infectious bronchitis commercial vaccines against recent local variant IBV isolated from Egypt at 2012.

2. Materials and Methods
Living infectious bronchitis vaccine:
Six IB commercial live attenuated vaccines were used; three variant IB Vaccines: Nobilis IB 4-91 Batch No. (A086J01); Gallivac IB 88 (CR 88121) Batch No. (L381024) and polyvac IB Primer (D274);
Variant infectious bronchitis virus (IB-IS/885):

A local field isolate of variant infectious bronchitis virus was kindly supplied by Dr. Rabab, Cairo poultry cooperation group (CPC). It was isolated from broiler flock, 24 day of age during an outbreak of IB in broiler farm in Egypt at May 2012. Clinical signs and lesions observed during the outbreak were an increase in mortality rate and nephritis. The variant virus was isolated from spleen and kidney of sick broiler in 9-11 day old embryonated SPF chicken eggs.

The strain was sequenced and identified by reference Lab for vet. Quality Control on Poultry Production. Virus titration was done using microtitre technique according to Rossiter and Jessett (1982) and calculated according to Reed and Muench (1938).

Experimental Hosts:

One day old SPF chicks: Chicks free from MDA (maternal driving antibodies) against IBV obtained from SPF poultry farm at Koum Osheim El-Fayoum, Egypt were used in this study. All birds were reared in cages and kept in a strict isolated mosquito proof room. The room was previously cleaned, thoroughly disinfected and provided with clean water and food.

Enzyme linked Immuno- Sorbent Assay (ELISA): (Snyder et al., 1986):

ELISA Kit was obtained from Biochek poultry immuno assays. Infectious Branchitis virus antibody test kit (CK 119); Serial No. F55419 product code: 5030.

Haemagglutination inhibition test (HI):

HI test was carried out according to Munir et al. (2012). Haemaggutinating (HA) antigens were prepared from chorioallantoic fluid harvested from IBV- inoculated embryonated SPF eggs and concentrated 100-fold by ultracentrifugation. The concentrated IBV strains were treated and used as HA antigens accordint to Mahmood et al., (2004).

Polymerase chain reaction (PCR): Council of Europe (1999):

PCR used for detect of Identity of commercial vaccines under test: RNA extraction kit using Bioflux Simply totat RNA extraction kit cat # (20111103). Amplification by using BIOER reverse transcription polymerase chain reaction (RT-PCR) kit one step cat # 20120603.

Statistical analysis:

It was applied using Epi-Info-Computer programme designed by Dean et al., (1994) and produced by World Health Organization (WHO). The calculation was according to Knapp and Miller (1991).

Experimental Design:

Eight groups of 30 SPF chicks each were used in the study. Birds from groups (1 to 6) were vaccinated via the nasal route with recommended dose of different examined commercial vaccines at one day old as shown in table (1). While birds in groups (7 & 8) were kept as control (+ve & -ve); respectively. Three weeks after vaccination; chickens from groups (1-7) were challenged simultaneously with 100 UL of IB (IS/885) challenge virus at dose of 4.0 log 10 EID₅₀ per 0.1 mL, administered via the oculi nasal route. Group 8 was left as an unchallenged control. Before challenge a blood sample was collected from each bird in order to determine the HI and ELISA antibody titer for different type of vaccines under test. Following challenge, all birds were observed daily for clinical signs attributable to IB infection.

3. Results

After IBV challenge, there was no mortality but at 48h after challenge; birds of group (7) - unvaccinated group- exhibited conjunctivitis, mainly of a third type with reluctant to move and in some cases presented with dyspnea. Food and water consumption were decrease with high rate in comparison with (-ve) control group (8). These symptoms regressed progressively in intensity until disappearance. Approximately 84h after challenge. Birds in groups (1-6) no clinical signs attributable to IBV infection were observed except very mild conjunctivitis in some birds in groups (1; 4; 5 & 6) that resolved within 48h and the clinical signs of tracheal rales were observed. Serological results, HI and ELISA test were applied to evaluate the antibody response in chickens (table -1).

Body weight: The body weights of chickens before IBD challenge at 21 days old were not significantly different (P> 0.05). At 7 days post challenge, the body weight of chickens in groups (1-6) which had received the vaccine was better than that of (group 7), the positive control. A significant difference (P <0.05) in body weight was found between birds in groups (3& 6) and the +ve control group as in table (2). Virus isolation and detection: The tracheal swaps and kidneys were separately collected from individual chickens for virus detection at 7 days post challenge. SPF eggs were used for virus isolation. IB (IS /885) was detected in the trachea and kidney of each chicken of all groups. The detection rate of the virus in the kidneys was higher than that of the trachea. The detection rate of the virus in the vaccinated groups was lower than that of the positive control group (G-7) with significantly difference (P <0.05). The rate of virus detection in
birds in groups (3 and 6) was lower than that of groups (1; 2; 4; and 5), but it was not significantly different (P > 0.05).

Histological examination: At 7 days post challenge, the kidney of non-vaccinated birds (G7) showed foci of necrosis and large amount of urates in ureters, which no lesions attributable to infection with IBV were observed in the vaccinated ones. (Fig: 3).

Fig (1): The embryos inoculated with the IB vaccine under test.

Fig (2): The PCR amplification of the spike gene from IB vaccines under test.

The amplification of the 300bp fragment of the vp gene of IB virus of six vaccine batches.
Fig (3): The histological examination.

(3.1) kidney of chicken in control SPF group showing the normal histological structure of glomeruli and renal tubules (H & E, 40x)

(3.2) kidney of SPF chicken experimentally infected by IB showing hyperemic blood capillaries and inflammatory cells infiltration in between the degenerated and necrotic tubules (H&E, 40x)

(3.3) Trachea of chicken in control SPF group showing the normal histological structure of mucosal layer cartilaginous layer. (H&E,40x)

(3.4) Trachea of SPF chicken experimentally infected by IB virus showing hyperplasia with polyps formation in the hyperemic lining mucosal layer. (H&E, 40 xs)

Table (1): Monitoring antibody response to different IB commercial vaccines (HI and ELISA)

<table>
<thead>
<tr>
<th>Test Group</th>
<th>Type of Vacc</th>
<th>GMT of ELISA Antibody titer</th>
<th>GMT of HI Antibody titer</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>IB 4-91</td>
<td>8068.00</td>
<td>7.60</td>
</tr>
<tr>
<td>G2</td>
<td>IB CR 88</td>
<td>3195.40</td>
<td>9.12</td>
</tr>
<tr>
<td>G3</td>
<td>IB Primer</td>
<td>5162.37</td>
<td>8.80</td>
</tr>
<tr>
<td>G4</td>
<td>M48</td>
<td>4850.00</td>
<td>9.50</td>
</tr>
<tr>
<td>G5</td>
<td>H 120</td>
<td>3871.00</td>
<td>10.0</td>
</tr>
<tr>
<td>G6</td>
<td>MA5</td>
<td>4210.10</td>
<td>9.90</td>
</tr>
<tr>
<td>G7</td>
<td>Control +ve</td>
<td>156</td>
<td></td>
</tr>
<tr>
<td>G8</td>
<td>Control –ve</td>
<td>156</td>
<td></td>
</tr>
</tbody>
</table>

GMT: Geometric mean titer
N.B.: Titer of control positive serum is equal or more than 3000 in ELISA antibody titer for IB living vaccine according to OIE (2010).
Significant difference at P ≤ 0.05
protection had been achieved. Our results agree with
virus in the tracheal mucosa. So that clinical
prohibited the invasion of the challenge. (IB-IS /885)
immunity in the upper respiratory tract which
be that live attenuated vaccines induced local
clinical protection against the challenge strain might
protection had been achieved. The reasons for the
vaccinated chickens, indicating that clinical
significantly lower  (P< 0.05) that of the none
chickens vaccinated with IBV vaccination were
(G8). The results of clinical protection showed in
were observed when compared with birds in group
Ma5 respectively and clinical signs of tracheal roles
examination. The results of clinical protection
detection at 7 days post challenge with histological
ELISA and HI. The last parameter was virological
Anti-body level against IBV which monitoring by
economical parameter especially in broiler flocks.
conjunctivitis being the primary sign of infection;
protection against weight loss as an important
respiratory signs in chickens vaccinated with all of
virus is isolated from No. less than 80% of control
vaccine protection is considered valid if the challenge
test to evaluate IBV (Council of Europe (2007))
According to the European Pharmacopoeia's Reference standards
(2010) Susan et al., (2011) and Sasipreeyajan. et al., (2012)A medium to low humoral response is in
finding of serum antibody titers which detected by
for differenet IB vaccines under test(7.6 -9.12 -8.80 -
strains.
As expected, the highest titers were
administration of live attenuated classical and variant
IB vaccines. As expected, the highest antibody titers than other
tests according to Mockett & Darbyshire (1981). Our
finding of serum antibody titers which detected by
ELISA technique who agree with
taking with that expected following the
living attenuated commercial vaccines in comparison
with unvaccinated negative control (156). The ELISA
Technique is a sensitive serological method and give
earlier reactions and higher antibody titers than other
tests according to Mockett & Darbyshire (1981). Our
finding of serum antibody titers which detected by
ELISA technique who agree with pensaert and
Lambrechts. (1994); Alvarado. et al., (2003); Hamel.
et al., (2006), Martin. et al., (2007), Salama. et.al.,
(2010) Susan et al., (2011) and Sasipreeyajan. et al., (2012).A medium to low humoral response is in
keeping with that expected following the administration of live attenuated classical and variant
IB vaccines. As expected, the highest titers were
obtained using antigens homologous to vaccine
strains.

4. Discussion
In this study, the efficacy of some living
classical and variant IBv vaccine which used in
Egyptian farms was evaluated after the challenge with
local variant (IB-IS/885) that isolated at May 2012
from broiler flock in Egypt. Four parameters were
used for the evaluation of the protection including
clinical protection based on conjunctivitis because the
conjunctivitis being the primary sign of infection;
protection against weight loss as an important
economical parameter especially in broiler flocks.
Anti-body level against IBV which monitoring by
ELISA and HI. The last parameter was virological
detection at 7 days post challenge with histological
examination. The results of clinical protection
showed no mortality and mild conjunctivitis in some
birds in birds vaccinated with 4-91; M48; H120 and
Ma5 respectively and clinical signs of tracheal roles
were observed when compared with birds in group
(G8). The results of clinical protection showed in
chickens vaccinated with IBV vaccination were
significantly lower  (P< 0.05) that of the none
vaccinated chickens, indicating that clinical
protection had been achieved. The reasons for the
clinical protection against the challenge strain might
be that live attenuated vaccines induced local
immunity in the upper respiratory tract which
prohibited the invasion of the challenge. (IB-IS /885)

The body weight affected in groups (4 & 5)
more than (1 & 2); while birds in group (3 & 6) the
rate of body weight near to control –ve group (G-8).
The same results could be detected by Sasipreeyajan
et al., (2012) which finding the body weight affect 7
days after using QX-Like IBV.

For studying potency effect in this trial; we used
two serological tests (CELISA and HI), ELISA
(GMT) gave 8068; 3195.4; 5162.37; 4850; 3871.0; 4210.1 when used different variant and classical
living attenuated commercial vaccines in comparison
with unvaccinated negative control (156). The ELISA
Technique is a sensitive serological method and give
earlier reactions and higher antibody titers than other
tests according to Mockett & Darbyshire (1981). Our
finding of serum antibody titers which detected by
ELISA technique who agree with pensaert and
Lambrechts. (1994); Alvarado. et al., (2003); Hamel.
et al., (2006), Martin. et al., (2007), Salama. et.al.,
(2010) Susan et al., (2011) and Sasipreeyajan. et al., (2012).A medium to low humoral response is in
keeping with that expected following the administration of live attenuated classical and variant
IB vaccines. As expected, the highest titers were
obtained using antigens homologous to vaccine
strains.

Our results in table (1) for mean log2 HI titers
for differenent IB vaccines under test(7.6 -9.12 -8.80 -
9.5- 10.0- 9.90)were agree with Macpherson and
Feest (1978); Macdonald et al., (1981); Elham et al.,
and Terregino et al., (2008)According to the
European Pharmacopoeia’s Reference standards
(Council of Europe (2007)) the test to evaluate IBV
vaccine protection is considered valid if the challenge
virus is isolated from No. less than 80% of control
group. A vaccine is considered effective if the
challenge virus is isolated from less than 20% of birds
vaccinated. All of the non vaccinated birds were
infected based on detection of virus in kidney and so

Table (2): Body weight before and after IBV challenge and clinical sign after IBV challenge:

<table>
<thead>
<tr>
<th>Test Group</th>
<th>Type of Vacc</th>
<th>*Body weight</th>
<th>**Clinical Sign</th>
<th>***No. of survived</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>3 ws old</td>
<td>4 ws old</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G-1</td>
<td>IB 4-91</td>
<td>1.201</td>
<td>1.500</td>
<td>2/30</td>
<td>28/30</td>
</tr>
<tr>
<td>G-2</td>
<td>IB 88</td>
<td>1.205</td>
<td>1.590</td>
<td>0/30</td>
<td>30/30</td>
</tr>
<tr>
<td>G-3</td>
<td>IB primer</td>
<td>1.310</td>
<td>1.699</td>
<td>0/30</td>
<td>30/30</td>
</tr>
<tr>
<td>G-4</td>
<td>M 48</td>
<td>1.205</td>
<td>1.460</td>
<td>2/30</td>
<td>28/30</td>
</tr>
<tr>
<td>G-5</td>
<td>H 120</td>
<td>1.207</td>
<td>1.500</td>
<td>5/30</td>
<td>25/30</td>
</tr>
<tr>
<td>G-6</td>
<td>M A 5</td>
<td>1.390</td>
<td>1.780</td>
<td>0/30</td>
<td>30/30</td>
</tr>
<tr>
<td>H-7</td>
<td>Cont. + Ve</td>
<td>1.400</td>
<td>1.450</td>
<td>30/30</td>
<td>0/30</td>
</tr>
<tr>
<td>H-8</td>
<td>Cont. –ve</td>
<td>1.405</td>
<td>1.807</td>
<td>0/30</td>
<td>30/30</td>
</tr>
</tbody>
</table>

*Mean of body weight
**Number of chickens with clinical signs / total chickens in group.
***Number of survived chickens till the end of test/total chicken.
Significant difference at P < 0.05

http://www.sciencepub.net/nature
the challenge experiment was successful. The presence of viable virus in kidneys confirms the ability of IB/885 challenge virus to replication and act as nephropathogenic potential as reported in case of IBV-QX by Liu and Kong (2004) and Terregino et al., (2008) and partially with Salama et al., (2010) when used virulent IBV (M41). For studying the relation between serological antibodies and results of protection percentage, it could be attributed to presence of local immunity of the upper respiratory tract induced by vaccination reduced the replication of challenge virus after challenge by the oculonasal route. Furthermore, immune responses directed to epitopes involved in protective immunity might not be fully detected by the HI test as reported by Cook et al., (1999); Worthington et al., (2004) and Terregino et al., (2008).

Based on the data presented in this study it can be concluded that, under experimental condition the IB variant (IB-88; IB primers) and classical one (Ma5) vaccines administered at 1 day protect chickens from infection and disease following challenge with local IB (IS/ 885) variant strain which recently isolated in Egypt at May 2012. This confirms that under field conditions we can use vaccination programs based on our results to reduce the economic losses caused by variant IB infection viruses in Egypt.

Corresponding author
Susan, S. El-Mahdy
Central Lab. for Eval. of Vet. Biol. Abbassia Cairo, Egypt (CLEVB)
Prof.s.elmahdy@gmail.com

References
41. Salama, S.S; Eman, A. Hasan; Hanan, E. Mohammed; Eman, S. Ahmed; Nadia, Ebrahim

11/20/2012